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OBJECTIVES: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. The aim of
this study is to analyze the three year screening rate (coverage) of
the organized cervical cancer screening programme in women
aged over 64 years. Although women over 64 years are out of the
scope of the organized screening programme, but opportunistic
screening may be applied. METHODS: The data derive from the
ﬁnancial database of the National Health Insurance Fund
Administration (OEP) of Hungary covering the period of 2000–
2002 (without organized screening) and 2003–2005 (with orga-
nized screening). We calculated the three-year screening rate for
2003–2005 according to the age-group of women over 64 years.
Screening is deﬁned with cytological examination of Papanicolau
smear and includes all smears taken either within or outside of
the organized programme. RESULTS: The 3-year screening rate
of women aged 25–64 years was 52.65% in 2003–2005. The
coverage of women over 64 years was the following in 2003–
2005: 65–69 years: 22.26%; 70–74 years: 14.73%; 75–79 years:
10.69%; over 80 years: 5.63%. Comparing this values to the
coverage of 2000–2002 (without organized screening) we found
controversary changes in the different age-groups: 65–69 years:
1.22 percentpoint increase, 70–74 years: -0.4 percenpoint
decrease; 75–79 years: -0.22 percentpoint decrease; over 80
years: 0.53 percenpoint increase. CONCLUSION: After the
introduction of organized cervical screening programme for
women aged 25–64, we found controversary effect (both increase
and decrease) on the coverage of women aged over 64. The effect
of organized screening programme on the coverage of women
out of the scope of this programme was not signiﬁcant.
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OBJECTIVES: Medication spending on oncology products (L01
ATC group) was steadily increasing during the past decade in
Czech Republic. The L01 market exceeded 100 million € in
2005, which represents approximately 6% of the total Czech
pharmaceutical market. This aim of this analysis is evaluation of
long-term developments in this segment and focus on the main
growth drivers. METHODS: Data covering the time period from
1992 to 2005 were obtained from a database of the Czech
Institute for Drug Control. The analysis was performed per ATC
subgroups, and identiﬁed (based on launched products and their
development over time) most important growth drivers.
RESULTS: The L01 market grew from 7.4 million € in 1992 to
133 million € in 2005. Over the past ﬁve years the L01 market
more than doubled (62 mil € to 133 mil €). This increase was
driven not only by enhanced consumption but also by increased
price per pack (from mean 96€/pack in 2001 to 187€/pack in
2005), reﬂecting introduction and usage of new costly molecules
in cancer therapy. Regarding ATC sub-groups, the major growth
is generated by products launched since 1996 (taxanes) and
especially after the introduction of protein kinase inhibitors,
monoclonal antibodies and other biotechnology products. CON-
CLUSION: The Czech L01 market shows similar growth rates
and trends as in other countries. The dynamics is driven by
biotechnology products. These currently in majorities cover
advanced metastatic cancer stages but we can expect them to
extend indications also to earlier cancer stages. Based on these
conclusions we can assume the L01 market to continue its
growth also in the near future.
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OBJECTIVES: The “Oncotype DX” 21-gene Recurrence Score
(RS) assay has been validated to quantify the likelihood of breast
cancer recurrence and the beneﬁt of providing adjuvant chemo-
therapy (CT) in addition to hormonal therapy, for node-negative
(N-), estrogen receptor positive (ER+) patients. In February
2006, Clalit Health Services (CHS), Israel, was the ﬁrst HMO
outside the USA to reimburse the assay, to assist physicians in the
decision whether or not to provide adjuvant chemotherapy to N-,
ER+ early-stage breast cancer patients. We evaluated the impact
of Oncotype DX on “real life” treatment decisions, as a basis for
the assay’s budget impact analysis. METHODS: We compared
the treatment offered prior to receiving RS results and the actual
treatment prescribed, for the ﬁrst nine months in which the assay
was reimbursed, and calculated the net impact on number
of patients receiving chemotherapy in this setting. Data was
collected from CHS’ computerized database and the pre-
authorization requests for Oncotype DX. RESULTS: 180
patients were included. Recurrence Score RESULTS: Low risk
(RS < 18), 37.5%; Intermediate risk (RS 18–30), 44.5% and;
high risk (RS > 31), 18%. CT was initially offered to 106/180
patients (59%). RS changed actual treatment in 71/180 patients
(39%); eliminating CT in 62 patients (34%) and adding CT in 9
patients (5%), a net reduction of 29% in chemotherapy pre-
scribed. CONCLUSION: RS changed the treatment decision in a
signiﬁcant proportion of N-, ER+ breast cancer patients, mostly
from CT to hormonal therapy alone, avoiding unwanted conse-
quences and costs of CT treatment. For budget impact calcula-
tions, we found an average of 3.5 Oncotype DX assays needed,
for every case of avoided adjuvant chemotherapy. Further savings
might be also in patients that were added CT, by reducing the
chance of metastatic disease. Additional studies are needed to
evaluate the short and long term economic implications and
cost-effectiveness of Oncotype DX use.
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OBJECTIVES: To estimate the country-speciﬁc incidence of men
with lower-risk (early-stage or localized) prostate cancer where
imperfect diagnostic information makes the decision to perform
radical prostatectomy (RP) uncertain. RP is indicated only when
early-stage tumors are fast growing or when localized prostate
cancer is strictly intra-capsular, neither of which can be ac-
curately determined with available diagnostic technology.
METHODS: We deﬁned early-stage prostate cancer (PC) as
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